Shire Shrugs Off Lifitegrast CRL; Launch Expected In 2016
This article was originally published in Scrip
Executive Summary
An early warning, and preparation, helped Shire PLC to blunt the impact of a US FDA complete response letter for its dry-eye candidate lifitegrast.